(Q42378160)

English

Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome

scientific article published on 29 August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

0 references

Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome (English)

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Elizabeth A Kessler

1

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

Sheetal S Vora

2

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

James W Verbsky

3

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

29 August 2012

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

Pediatric Rheumatology Online Journal

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

10

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

1

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

30

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

https://scigraph.springernature.com/pub.10.1186/1546-0096-10-30

0 references

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3511797

28 May 2018

Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3511797

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3511797

28 May 2018

Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22931129

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6

1 reference

https://pubmed.ncbi.nlm.nih.gov/22931129

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Juvenile idiopathic arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22931129

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1546-0096-10-30

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42378160&oldid=1943140877"